In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.41 a new company low.

Within Major Pharmaceutical Preparations industry 399 other companies have achieved higher Quick Ratio than Gossamer Bio Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1527, from total ranking in the first quarter 2026 at 1621.

Explain Quick Ratio?
How much Cash & cash equivalents GOSS�s has?
What are GOSS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GOSS Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	157.09 %	17.18 %	40.94 %	21.6 %	18.61 %
Y / Y Cash & cash equivalent Change	-73.22 %	-61.53 %	-53.51 %	-44.89 %	-39.94 %
Quick Ratio MRQ	0.41	1.76	2.16	2.9	3.97
GOSS's Total Ranking	# 1527	# 1621	# 1256	# 1064	# 860
Seq. Current Liabilities Change	143.84 %	-10.92 %	2.12 %	15.9 %	11.14 %
Seq. Cash & cash equivalent Change	-42.52 %	-27.54 %	-24.02 %	-15.36 %	-17.45 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 400
Healthcare Sector	# 758
Overall Market	# 2794

Quick Ratio Statistics
High	Average	Low
38.72	12.05	0.41
(Mar 31 2019)		(Jun 30 2026)

Financial Statements
Gossamer Bio Inc 's Current Liabilities	$ 138 Millions	Visit GOSS's Balance sheet
Gossamer Bio Inc 's Cash & cash equivalent	$ 57 Millions	Visit GOSS's Balance sheet
Source of GOSS's Sales		Visit GOSS's Sales by Geography

Cumulative Gossamer Bio Inc 's Quick Ratio

GOSS's Quick Ratio for the trailling 12 Months

GOSS Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	61.61 %	24.35 %	28.39 %	13.75 %	13.15 %
Y / Y Cash & cash equivalent TTM Growth	-56.66 %	-49 %	-35.43 %	-22.64 %	-10.77 %
Quick Ratio TTM	1.48	2.67	3.47	4.53	5.52
Total Ranking TTM	# 2026	# 2438	# 1691	# 1509	# 1147
Seq. Current Liabilities TTM Growth	35.73 %	3.64 %	8.82 %	5.57 %	4.44 %
Seq. Cash & cash equivalent TTM Growth	-24.77 %	-20.14 %	-16.67 %	-13.44 %	-11.47 %

Quick ratio ranking by company, industry and sector >> Back to GOSS Financial Strength Comparisons >> Go to Compare GOSS Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $137.78 millions, cumulative Quick Ratio decreased to 1.48 below the Gossamer Bio Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Gossamer Bio Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2992.

Explain Quick Ratio?
How much Cash & cash equivalents GOSS�s has?
What are GOSS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 440
Healthcare Sector	# 903
Within the Market	# 1527

trailing twelve months Quick Ratio Statistics
High	Average	Low
14.61	4.29	0.4
(Mar 31 2021)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Emergent Biosolutions Inc	1.14	$ 139.700 Millions	$ 122.800 Millions
Turn Therapeutics Inc	1.14	$ 9.958 Millions	$ 8.764 Millions
Ionis Pharmaceuticals Inc	1.11	$ 350.065 Millions	$ 315.638 Millions
Oramed Pharmaceuticals Inc	1.00	$ 16.091 Millions	$ 16.044 Millions
Inmed Pharmaceuticals Inc	1.00	$ 2.240 Millions	$ 2.235 Millions
Nkarta Inc	1.00	$ 24.958 Millions	$ 24.924 Millions
Inovio Pharmaceuticals Inc	1.00	$ 36.700 Millions	$ 36.678 Millions
Jazz Pharmaceuticals Plc	0.98	$ 2,199.800 Millions	$ 2,239.400 Millions
Akebia Therapeutics Inc	0.97	$ 155.548 Millions	$ 160.865 Millions
Syndax Pharmaceuticals Inc	0.95	$ 342.883 Millions	$ 360.284 Millions
Nurix Therapeutics Inc	0.94	$ 67.840 Millions	$ 72.020 Millions
Theriva Biologics inc	0.94	$ 11.337 Millions	$ 12.111 Millions
Geron Corporation	0.92	$ 64.781 Millions	$ 70.331 Millions
Zomedica Corp	0.84	$ 7.605 Millions	$ 9.002 Millions
Cocrystal Pharma Inc	0.83	$ 2.169 Millions	$ 2.616 Millions
Harrow Inc	0.82	$ 83.889 Millions	$ 102.171 Millions
Cue Biopharma Inc	0.82	$ 17.414 Millions	$ 21.218 Millions
Zoetis Inc	0.81	$ 1,676.000 Millions	$ 2,061.000 Millions
Organogenesis Holdings Inc	0.81	$ 46.097 Millions	$ 56.963 Millions
Bridgebio Pharma Inc	0.81	$ 720.160 Millions	$ 890.648 Millions
Nrx Pharmaceuticals Inc	0.79	$ 26.686 Millions	$ 33.874 Millions
Oncolytics Biotech Inc	0.79	$ 4.115 Millions	$ 5.225 Millions
Moleculin Biotech Inc	0.78	$ 7.262 Millions	$ 9.313 Millions
Seres Therapeutics Inc	0.78	$ 15.594 Millions	$ 20.031 Millions
Travere Therapeutics Inc	0.77	$ 117.735 Millions	$ 152.025 Millions
Arcus Biosciences Inc	0.77	$ 153.000 Millions	$ 198.000 Millions
Alkermes Plc	0.77	$ 511.529 Millions	$ 662.091 Millions
Integrated Biopharma Inc	0.77	$ 4.471 Millions	$ 5.802 Millions
Cyclerion Therapeutics Inc	0.75	$ 1.391 Millions	$ 1.843 Millions
Dar Bioscience Inc	0.75	$ 12.618 Millions	$ 16.923 Millions

Date modified: 2026-09-26T07:36:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.